Glomerular Diseases: Update for the Clinician
Open Access

All Things Complement

Joshua M. Thurman and Carla M. Nester
CJASN October 2016, 11 (10) 1856-1866; DOI: https://doi.org/10.2215/CJN.01710216

Abstract

The complement (C) cascade is an ancient system of proteins whose primary role is to initiate and modulate immune responses. During C activation, circulating proteins are cleaved and nascent cleavage fragments participate in a broad range of downstream innate and adaptive immune functions. Although the majority of these functions are either homeostatic or protective, a large body of experimental and clinical evidence also highlights a central role for the C system in the pathogenesis of many types of glomerular disease. From classic pathway activation in lupus nephritis to alternative pathway dysregulation in C3 glomerulopathy, our understanding of the spectrum of C involvement in kidney disease has expanded greatly in recent years. However, the characteristics that make the glomerulus so uniquely susceptible to C-mediated injury are not fully understood, and this remains an area of ongoing investigation. Several C inhibitors have been approved for clinical use, and additional C inhibitory drugs are in development. The use of these drugs in patients with kidney disease will expand our understanding of the benefits and limitations of C inhibition.

Introduction

The complement (C) system is a complex group of interacting proteins that play a critical role in host immune surveillance and defense. C activation results in the generation of multiple protein fragments that mediate biologic processes integral to both health and disease (Table 1) (1). In addition to the well described homeostatic functions of C, a pathologic role for C activation has emerged for a number of the glomerular diseases (Table 2). In many of these diseases, immune-complexes (ICs) trigger activation of the classic pathway (CP). Other diseases, such as atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), are associated with defective regulation and/or enhanced activation of the alternative pathway (AP). Additional details regarding the role of C in membranous nephropathy, antiglomerular basement membrane (GBM) disease, and antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis were discussed in a recent Clinical Journal of the American Society of Nephrology educational review (2). Other glomerular diseases in which C activation likely plays a critical role will be reviewed in subsequent articles in this series.

View this table:
Table 1.

Functions of the C cascade

View this table:
Table 2.

Evidence that the C system is involved in glomerular diseases

Although the mechanisms of C activation and C-mediated injury may vary, the critical role of the C system in glomerular diseases of such diverse etiologies indicates a unique susceptibility of the kidney to the injurious effects of C. In this review we present an overview of the C cascade and evidence that C plays a role in glomerular disease, and we discuss recent advances in C biology that inform the treatment of glomerular disease.

Overview of the C Cascade

C Activation Pathways

The C cascade is comprised of >30 circulating proteins that are activated through one of three initiation pathways (Figure 1) (3). Multiple different molecules can trigger C activation. IgG (particularly the IgG3 and IgG1 isotypes), IgM, C-reactive protein, and serum amyloid P activate the CP. The mannose binding lectin pathway is activated when circulating lectin binds to sugar moieties on pathogens. C4b is deposited on tissues after activation of the CP or mannose binding lectin pathway, and it composes part of the CP C3-convertase (Figure 2).

Figure 1.
Figure 1.

Overview of the C cascade. The C cascade can be activated through the classic pathway, the alternative pathway, and the mannose binding lectin pathway. Activation through each of these pathways generates C3-convertases (shown in blue font), enzyme complexes that cleave C3 and generate C3b. Further amplification of C activation through the alternative pathway generates additional C3b. C3b combines with the C3-convertases to create C5-convertases (shown in green font), enzyme complexes that cleave C5. Full activation of the C cascade generates several proinflammatory fragments: C3a, C3b, C5a, and C5b-9 (shown in red font). Although the C system is activated in most forms of glomerular disease, the mechanisms of activation and the pathways involved are distinct. Some of the diseases in which each pathway is involved are listed.

Figure 2.
Figure 2.

Fate C3 and C4 fragments on cell surfaces. The cleavage of C3 and C4 allows the covalent attachment to cell and tissue surfaces of C3b and C4b, respectively. Deposited C3b composes part of the alternative pathway C3-convertase. This complex is stabilized by properdin and generates additional C3b unless the convertase decays or C3b is inactivated (cleaved) by the plasma protease factor I, generating iC3b. The decay of the convertase is accelerated by some regulatory proteins (not shown in this figure). To inactivate C3b, factor I requires cofactor proteins. Membrane cofactor protein and C receptor-1 (CR1) are cell surface cofactors, and factor H is a soluble cofactor. CR1 also serves as a cofactor for cleavage of iC3b to C3dg. Deposited C4b composes part of the classic pathway C3-convertase and generates C3b unless the convertase decays or C4b is inactivated (cleaved) by factor I. Membrane cofactor protein and CR1 are cell surface cofactors for the cleavage of C4b, and C4 binding protein (C4bp) is a soluble cofactor for this process.

The CP is not simply a downstream effector of tissue injury in IC-mediated diseases, but it also functions to prevent the development of autoimmunity. In fact, congenital deficiencies of the early CP proteins (C1q, C2, and C4) are among the strongest risk factors for developing lupus (4). This association may be due to impaired phagocytosis of apoptotic cells and nuclear debris in the absence of the CP (Table 1) (5). The risk of developing autoimmunity to these nuclear antigens increases because of their prolonged presence outside of cells (5). Opsonization of antigens with C also lowers the activation threshold of B cells, and C deficiencies may hinder the elimination of autoreactive B cells (5). Thus, the CP reduces the risk of autoimmunity, but also mediates tissue injury caused by autoantibodies.

Some molecules, such as IgA, can directly activate the AP (6), but this pathway does not require specific protein–protein interactions and is constitutively active as a result of spontaneous hydrolysis of C3. Additional details of the molecular interactions involved in C activation are described in an excellent recent review (2).

Activation through any of the C pathways leads to the proteolytic cleavage and activation of C3 (3). Activated C3, referred to as C3b, is central to all three pathways. C3b contains a thioester bond that can form covalent amide or ester bonds with amino and hydroxyl groups on cell surfaces. C3b is also a key component of the AP C3-convertase, an enzyme that cleaves additional C3 (Figures 1 and 2). As a result, C activation through any of the initiation pathways rapidly self-amplifies as C3b fosters the generation of yet more C3b, and millions of the molecules can be formed and deposited on target surfaces within minutes (7). The addition of a C3b molecule to the C3-convertases generates C5-convertases, enzymes that cleave the protein C5.

C activation causes kidney injury through direct effects on renal cells and through interactions with cells of the innate and adaptive immune systems. Receptors for C3b are expressed on erythrocytes, leukocytes, and nonhematologic cells, and engagement of these receptors mediates cell activation and phagocytosis (2). Small soluble peptides referred to as anaphylotoxins (C3a and C5a) are also generated during C activation. C3a and C5a receptors are expressed on leukocytes, endothelial cells, mesangial cells, and tubular epithelial cells (2). These fragments trigger systemic inflammatory responses through their receptors, including vascular changes and the chemotaxis of immune cells. C3a directly induces mesangial cells to proliferate and secrete extracellular matrix (8), and it causes tubular epithelial cells to produce proinflammatory chemokines (9). Finally, full activation of the C pathways generates C5b-9 (the membrane attack complex) a multimeric structure that forms pores in the membranes of target cells, causing cell activation and lysis. C5b-9 causes endothelial cells to release mitogens that promote mesangial proliferation (10). When C5b-9 is generated directly on the surface of mesangial cells it triggers production of prostaglandins, cytokines, and reactive oxygen species (11,12). Formation of C5b-9 on podocytes is an important cause of glomerular injury in membranous disease (13).

C Regulatory Proteins

To protect host cells from uncontrolled C activation, several C regulatory proteins are expressed on the surface of cells and also circulate in plasma (14). These proteins inactivate the C convertases by dissociating them or by cleaving C3b to form iC3b (Figure 2; see also Mathern and Heeger [2]). Further degradation of iC3b yields C3d, which remains covalently attached to target surfaces. Like C3b, the C4b protein has an internal thioester bond that can form covalent bonds with tissue surfaces (15). Inactivation (cleavage) of C4b by regulatory proteins yields C4d, which also remains attached to tissues (Figure 2).

Factor H is a soluble regulator of the AP that is particularly important for protecting the kidney. Although it is only one of several C regulators that function in the glomerulus, a large body of evidence indicates that defects in the function of factor H are sufficient to cause glomerular injury (16). Factor H is comprised of 20 repeating structural domains (short consensus repeats, or SCRs). The C regulatory function of factor H is performed by the first four SCRs, whereas several other regions of the protein mediate binding of the protein to tissue surfaces. The carboxy terminus of factor H (SCRs 19–20) binds to C3b and glycosaminoglycans (17) and confers the ability to bind and protect endothelial cells. Five C factor H–related proteins (CFHRs) arose through gene reduplication and share structural similarities to factor H (18). These proteins each contain the SCR 19–20 binding domain, but they do not contain the SCR 1–4 C regulatory domain. The function of the CFHRs is controversial. Experiments have shown that they can regulate C activation in some settings, but the binding domains may also competitively inhibit factor H from functioning on some surfaces (14,18).

The degree to which C is activated in a given tissue is a dynamic process and depends on a number of factors. Cell injury may reduce the surface expression of regulatory proteins (19) and stimulate local production of C proteins by renal cells (20). Both of these cellular responses promote C activation. Other biologic systems also interact with the C cascade. Notable examples include the activation of C5 by thrombin (21), and local impairment of factor H by the protein annexin A2 (22).

Evidence That the C System is Involved in Glomerular Diseases

As early as the 1960s it was understood that the C system was involved in antibody-mediated glomerular injury (23), and by the 1970s C proteins were detected in renal biopsy specimens from patients with GN (24). Experimental evidence in both animal models and in patients links the C system with a large number of glomerular diseases (Table 2).

Clinical Biomarkers of C Activation

Tissue Staining.

Activation of the C cascade generates several soluble and tissue bound protein fragments, and these fragments can be employed as biomarkers of tissue inflammation. Kidney biopsies are routinely immunostained for deposits of C3 and C4 fragments. Tissue staining for C3 is usually performed using an antibody to C3c, which detects tissue-bound C3b and iC3b (Figure 2). Because C3b is deposited on target tissues by all three activation pathways, detection of these fragments is interpreted as a catch-all marker of C activation. The C4d fragment remains attached to surfaces after C4 inactivation. Detection of C4d is now routinely used as a marker of antibody-mediated rejection, but is also an indicator of active disease in IC-mediated GN (25). Biopsies are also sometimes immunostained for C1q, which is another marker of CP activation. In IC-mediated GN, Ig, C3 fragments, and C4 fragments generally colocalize (26). The detection of C3 in the absence of Ig or C4 is a sign of an AP-mediated process (Figure 1), and is the basis of the diagnosis of C3G (27).

C Protein Levels.

Decreased levels of plasma C3 and C4 have long been associated with active inflammation in patients with autoimmune and systemic inflammatory diseases (28). The levels of these proteins are determined by their rate of synthesis (primarily in the liver, but also by renal cells) and the rate of consumption. They are sensitive indicators of activity in some diseases, such as diffuse proliferative lupus nephritis (28). Conditions in which hepatic production of C proteins is altered can confound the interpretation of low C levels. Production of the C proteins increases in pregnancy, for example, whereas it decreases in patients with cirrhosis (28). Furthermore, the levels remain normal in many C-mediated diseases. This may be because local C activation can cause significant tissue injury without depleting the plasma pool of C3, or that activation is driven by locally produced C3 (20). In contrast, it was reported that C3 levels remained depressed in a patient with membranoproliferative GN who underwent bilateral nephrectomy, demonstrating that the consumption of C3 can occur in the plasma or tissues outside of the kidneys (29).

Several clinical studies have measured C activation fragments in plasma and urine as biomarkers of active kidney disease. C activation fragments may be useful for predicting disease flares in patients with lupus, particularly if the level of intact C3 is confounded by pregnancy or other clinical conditions (30). Urinary C3d and C5b-9 are biomarkers of immunologic glomerular injury in patients with membranous nephropathy (31). Given that the drug eculizumab blocks the cleavage of C5, it is logical that detection of sC5b-9 would be a useful guide to eculizumab therapy, but local C activation may not always cause detectable increases in the systemic levels of sC5b-9 (32). In addition, the C proteins are labile, and measurement of the activation fragments is sensitive to sample handling. These issues must be considered when interpreting biomarker findings.

Animal Models

Both naturally occurring and laboratory-generated animal models have been instrumental in our understanding of the role of C in the glomerular diseases. GN in a strain of Norwegian Yorkshire pigs was caused by congenital deficiency of factor H (33). Mouse models of C deficiency have defined a role for C in both IC-mediated glomerular diseases (34) and in glomerular injury in the absence of Ig (35). More recently, animal models led to the discovery that C activation contributes to diseases such as ANCA-associated vasculitis (36) and FSGS (37), diseases not previously considered to be C-mediated. Animal models have also been instrumental in demonstrating the efficacy of C therapeutics before clinical trials (38,39).

There are several differences between the mouse and human C systems that limit the applicability of mouse models to human disease. Although the general organization of the cascade is the same, structural differences between mouse and human proteins prevent some human therapeutics from working in mice. Eculizumab, for example, does not inhibit mouse C5 (40), and compstatin (a small molecule inhibitor of human C3) does not inhibit mouse C3 (41). Mouse C also has lower lytic activity than that of other species, possibly because murine C4 does not generate an effective CP C5-convertase (42). The role of C5b-9 may therefore be underrepresented in murine models of IC-mediated diseases. The study of IC-mediated glomerular disease is also complicated by differences between rodents and humans in the mechanisms of IC clearance. In humans, C receptor-1 (CR1) on erythrocytes binds to C3b containing ICs and transports them to the liver. In rodents, on the other hand, ICs are transported to the liver by platelets, and adherence of the ICs is mediated by factor H on the platelet surface instead of CR1 (43).

Molecular Studies

A large number of different molecular abnormalities are associated with C dysregulation within the glomerulus (44–46). Rare variants in the genes for factor H, C3, factor B, factor I, membrane cofactor protein (MCP, or CD46), and thrombomodulin have been identified in patients with aHUS (46,47). Studies have also revealed that rare variants and hybrid forms of the CFHR genes are associated with aHUS (18,48–52), and deletion of CFHR1–3 is associated with the development of autoantibodies to factor H, an abnormality that is found in approximately 10% of aHUS patients (53).

C3 nephritic factor (an autoantibody against the AP C3-convertase) is the most common C abnormality found in patients with C3G (54). A number of genetic impairments in AP regulation have also been identified in patients with this disease, including variants in the genes for factor H, factor B, C3, and the CFHRs (27,44,45,55). Experimental analyses of the disease-associated CFHR variants suggest that they impair the ability of factor H to control AP activation on tissue surfaces (18,56).

All of these molecular defects are associated with uncontrolled activation of the AP, and in some cases a causative relationship between the genetic abnormality and functional C dysregulation has been confirmed experimentally (57). From a diagnostic perspective, however, the large number of possible genetic variants and autoantibodies makes the analysis of individual patients complicated. Nevertheless, testing for genetic variants and autoantibodies can help establish the diagnosis, and identifying autoimmune causes of C dysregulation can guide immunosuppressive treatment (58).

Mechanisms of C Activation in Glomerular Diseases

Pathologic C activation within host tissues involves: (1) molecular events that promote C activation (e.g., IC deposition), and/or (2) local impairments in the regulation of C activation. These mechanisms are not mutually exclusive, as ICs cause CP activation but can also create a microenvironment from which C regulators are excluded (59). All of the resident renal cells express C regulatory proteins (16). Yet, the frequent involvement of the C system in renal disease demonstrates that the regulatory capacity of these proteins can be overwhelmed or subverted.

Vasculature and Glomerular Endothelial Cells

Subendothelial deposition of ICs is common in lupus nephritis and membranoproliferative GN (Figure 3). IgG and IgM containing ICs activate the CP, causing direct injury and inflammation of nearby tissues. Animal models also demonstrate that injury of the glomerulus in IC-mediated diseases involves amplification through the AP (34,60). In aHUS, the AP may be activated directly on glomerular endothelial cells due to impaired regulation. Even in patients with a genetic predisposition to aHUS, however, the majority of flares occur after a systemic illness or stressor (61). A recent study reported that C1q and C4d can be seen in the vasculature of most patients with aHUS (62). It is possible that illness or endothelial damage triggers C activation through the CP, but that uncontrolled AP activation perpetuates microvascular injury in susceptible patients. The AP is also critical for the development of ANCA vasculitis (36), although the exact mechanism and location of AP activation are not yet known.

Figure 3.
Figure 3.

Conditions within the kidney that are conducive to C activation. The C cascade is activated by distinct mechanisms at various ultrastructural locations within the kidney. Immune-complexes can deposit in the mesangium and at different locations within the glomerular capillary wall. In some diseases, autoantibodies bind to specific renal antigens. Other conditions in the kidney that favor C activation are increased concentrations of C proteins in the efferent vessels, low pH, increased local concentrations of C proteins due to production by tubular epithelial cells, and high concentrations of ammonia which can activate the alternative pathway. The glomerular basement membrane does not express C regulatory proteins, although factor H controls alternative pathway activation on the glomerular basement membrane. The apical surface of tubular epithelial cells also does not express C regulatory proteins, and alternative pathway proteins may be activated at this location in proteinuric conditions. EC, endothelial cell; PO, podocyte; fB, factor B; fD, factor D.

GBM

In contrast to cells, basement membranes do not intrinsically express regulatory proteins and are dependent on circulating factor H to control AP activation (2). Genetic defects (61), autoantibodies (53), or other proteins can interfere with the function of factor H (22). Factor H deficiency is associated with C activation in the fluid phase and directly on the GBM (63), mechanisms that are believed to cause C3G (Figure 4). Dysregulation of the AP results in C3 deposits in the relative absence of Ig, and this is the diagnostic basis of C3G (27). Dense deposit disease is a subtype of C3G characterized by detection of electron dense deposits in the GBM by electron microscopy (27). The composition of these deposits is not known, but similar deposits are seen in factor H deficient mice (35). Antibodies to the noncollagenous-1 domain of type 4 collagen directly activate C on the GBM (2). Activation is initiated through the CP in that setting, but detection of AP proteins suggests that this pathway is also involved (2).

Figure 4.
Figure 4.

Molecular defects in C regulation associated with C3 glomerulopathy and atypical hemolytic uremic syndrome. In health, factor H controls C activation in the fluid phase and on the glomerular basement membrane. Factor H and cell surface C regulatory proteins (MCP, membrane cofactor protein; DAF, decay accelerating factor; THBD, thrombomodulin) control C activation on glomerular endothelial cells. In patients with C3 glomerulopathy, congenital or acquired defects probably cause dysregulated C activation in the fluid phase and/or on the glomerular basement membrane. In atypical hemolytic uremic syndrome, congenital or acquired defects probably cause dysregulated C activation on glomerular endothelial cells. Defects in C regulation in the different conditions are indicated with red boxes or red font.

Podocytes

ICs are often seen in the subepithelial space of patients with membranous disease. IgG binds to the M-type phospholipase A2 receptor on podocytes in some patients (64), and other podocyte antigens have also been identified (65). Podocytes express CR1, which can regulate the CP and AP, but CR1 is cleaved from the surface of the cells in patients with lupus nephritis (66). The loss of CR1 may permit C activation at this location, or it may be a consequence of C5b-9 formation (66).

Mesangium

ICs deposit in the mesangium in several different types of GN, including lupus nephritis, causing C activation. Patients with C3G can also present with C3 deposits in the mesangium (55), indicating that factor H is functionally important for controlling AP activation at this location even though mesangial cells express cell surface C regulators (16). In IgA nephropathy ICs containing IgA1 deposit in the mesangium, similar to other IC-mediated glomerular diseases (67). Not surprisingly, there is extensive clinical evidence of glomerular C activation in patients with this disease (68). Unbiased genome wide association studies have also identified variants in CFH and the CFHRs that strongly associate with the risk of developing IgA nephropathy (69,70). Thus, the disease may be caused by the formation of IgA1 containing ICs, but injury of the glomerulus may also be determined by an individual’s ability to regulate amplification through the AP.

Tubulointerstitium

There is minimal expression of the C regulatory proteins on the apical surface of tubular epithelial cells (16). Ordinarily this surface does not come in contact with C proteins, but the AP may cause tubulointerstitial injury in patients with proteinuric kidney diseases due to free passage of C proteins into the tubules (71). Tubular epithelial cells also synthesize C3, and locally produced C3 may be an important cause of acute and chronic tubulointerstitial injury (20,72). Other conditions in the tubulointerstitium also favor AP activation. Ammonia can form an amide linkage with C3 and activate the AP. In settings of reduced nephron mass, the amount of ammonia produced by each nephron increases to maintain acid-base balance, and this adaptation may drive progressive tubulointerstitial inflammation and damage (73).

The Unique Susceptibility of the Glomerulus to C-Mediated Injury

In spite of intensive study, it still is not known why the glomerulus is so uniquely vulnerable to C-mediated injury. Factor H circulates in plasma and should control AP activation throughout the body. Similarly, MCP is expressed on endothelial cells and other cells throughout the body. Why, then, do genetic defects in these proteins primarily cause inflammation within the glomerulus? Other attributes of the microenvironment within the kidney (concentrated plasma proteins, local production of C proteins, and pH) likely contribute to C activation (Figure 3). Nevertheless, further study is needed in order to fully understand all of the mechanisms that cause pathologic C activation in the kidney.

Why Do Some Defects in AP Regulation Cause C3G and Some Cause aHUS?

Impaired AP regulation by factor H is strongly associated with both aHUS (61,74) and C3G (27,45,55), yet these diseases are clinically and pathologically distinct. The majority of the genetic variants in factor H associated with aHUS affect the carboxy terminus of the protein (61,74). As the carboxy terminus facilitates binding to cell surfaces, dysfunction in this region may limit the ability of factor H to protect glomerular endothelial cells from the AP (Figure 4). Autoantibodies to factor H also predominantly affect this region of the protein (75). The defects in MCP, factor I, C3, factor B, and thrombodmodulin that are associated with aHUS are also believed to impair regulation of the AP on the endothelial cell surface (61,74).

The autoimmune and genetic defects associated with C3G, on the other hand, tend to affect C regulation by the protein (Figure 4). The most common C defect in C3G is the presence of C3 nephritic factor, an autoantibody that protects the AP C3-convertase from inactivation by factor H (45,54). Genetic variants in C3 and factor B that confer resistance to inactivation of the C3-convertase by factor H (and hence, overactivity of the convertase) have also been found in patients with C3G (57). A variety of different histologic patterns and ultrastructural changes are observed in patients with C3G (45,55), but it remains unclear whether these are related to the associated C abnormalities.

The factor H defects that cause aHUS and C3G have been recapitulated in mice. Homozygous factor H deficiency caused C3G-like disease (35), whereas a partial deficiency in the carboxy-terminus of factor H was associated with aHUS-like disease (76). This paradigm does not apply to all patients, however, and some of the genetic variants associated with aHUS have also been identified in patients with C3G (45). Thus, more work is needed to identify the additional environmental, genetic, and epigenetic factors that influence the development and course of these diseases.

C As a Therapeutic Target

In aHUS and C3G, C activation is the primary insult that causes glomerular injury. Consequently, agents that prevent C activation will block the underlying process that causes these diseases. For antibody-mediated diseases, C inhibition may reduce inflammatory effects of ICs deposited within the glomerulus. In addition, C blockade may reduce T cell activation at the antigen presenting cell–T cell interface as well as the B cell response to antigens, thereby reducing the magnitude of the adaptive response to antigens (2).

Eculizumab is a monoclonal antibody that blocks the cleavage of C5, preventing formation of C5a and C5b-9 (40). In phase 2 clinical trials, treatment with eculizumab led to a rapid increase in the platelet count and steady improvement in renal function (77,78), and it has been approved for treatment of aHUS. These studies have demonstrated the safety and efficacy of C inhibition in patients with glomerular disease, and that inhibition can be maintained chronically.

Data suggest that eculizumab is superior to plasma exchange/infusion for the treatment of aHUS, although it is not effective in all patients (77,78). The response to treatment does not seem to depend upon identification of a genetic defect in a C-related gene (77,78), although a small subset of patients are resistant to the drug due to a genetic variant in the C5 gene (79). Earlier treatment with eculizumab is associated with better renal outcomes (80), and patients with worse renal function at presentation are less likely to achieve complete remission of thrombotic microangiopathy-related symptoms (77). This may be due to the presence of irreversible renal damage at the time of treatment. It is also possible that C3a and C3b/iC3b/C3d contribute to the pathogenesis of renal injury (9,81,82), and drugs that target the C system at the level of C3 or higher may be advantageous in some patients. Hemolytic uremic syndrome can also be caused by a variety of different systemic stressors, including drugs, autoimmune disease, hypertension, infections, cancer, and pregnancy (83). It is not yet clear whether eculizumab is beneficial in these settings, although there is evidence that pregnancy-associated hemolytic uremic syndrome is usually C-related (84).

Eculizumab has also been used off label for several other renal diseases, including C3G (85), catastrophic antiphospholipid antibody syndrome (86), lupus nephritis (87), and IgA nephropathy (88). Eculizumab only appears to be beneficial in a subset of patients with C3G. Earlier treatment is associated with a better response, so some of the patients may have already had irreversible renal injury by the time they were treated (85). Different underlying C defects may lead to C3 activation in the fluid phase or directly on the GBM (Figure 4), and these differences could affect how important C3 fragments are in the disease. Patients with elevated levels of C5b-9 (i.e., evidence of active terminal C activation) may be those most likely to benefit from eculizumab (85). It is not clear at this time whether the level of C blockade is the key to successful treatment, or whether earlier intervention would suffice.

Many other C inhibitors are currently in development (89). Monoclonal antibodies that target other C proteins have been tested, including antibodies to C1s, factor D, factor B, properdin, C3b, and the mannose associated serine proteases. Small molecules have been developed to block signaling of C3a and C5a at their receptors and can be administered subcutaneously or orally. C5a blockade was protective in a murine model of ANCA vasculitis (90), and the C5a receptor antagonist used in that study is currently being tested in a clinical trial of patients with ANCA vasculitis (ClinicalTrials.gov identifier: NCT02222155). Engineered proteins that specifically block C activation at sites of tissue injury and small interfering RNA agents that knock-down the production of C proteins are also in development. Each of the different therapeutic strategies has advantages as well as limitations, and the utility of these agents relative to eculizumab are discussed in a recent review (91).

Because the C system is an important part of the immune system, the major risk of all therapeutic C inhibitors is likely to be that of infection. Deficiency or blockade of the terminal C proteins is primarily associated with meningococcal infections (92). Patients treated with eculizumab should be immunized against Neisseria meningitides and/or prophylactically treated with antibiotics. In spite of immunization, approximately 1% of treated patients per year develop Neisserial infections (93). It has been suggested that antibodies to the organism are less effective in the setting of C inhibition. Drugs that block the C system higher in the cascade might also increase the risk of infection with encapsulated bacteria (92).

Conclusions and Future Directions

It has been known for >50 years that the C system plays an important role in IC-mediated glomerular injury, yet the field of C biology continues to rapidly change as new discoveries are made. Although aHUS and C3G are rare diseases, they are extreme examples of AP dysregulation that provide crucial insight into the biology of the AP. Careful examination of patients with these diseases has resulted in major advances in our understanding of C activation and C regulation within the glomerulus. These advances were made possible by multicenter clinical trials as well as multinational disease registries. The knowledge gained by these studies has already affected the care of these two diseases, and it has also informed our understanding of more common glomerular diseases. The connection between CFHR1–3 deletion and IgA nephropathy was discovered by a genome wide association study (69), for example, but our understanding of the function of the CFHRs is due to careful study of patients with aHUS and C3G.

There is still a great deal to be learned regarding the mechanisms by which the C system is activated within the glomerulus, the roles of the different C activation fragments in glomerular injury, and the optimal use of C inhibitory drugs in patients with kidney disease. New molecular causes of aHUS and C3G will undoubtedly be discovered that will improve our understanding of these diseases. Genetic studies of patients with other glomerular diseases will also reveal disease-specific as well as generalized mechanisms that increase or decrease the risk of glomerular disease. Given the complexity of the C system and the large number of molecules involved in C activation and regulation, this field may particularly benefit from large scale genomic and proteomic studies of patients with GN. Perhaps most importantly, as additional patients with glomerular diseases are treated with C inhibitory drugs, efforts must be made to gain further insights into the risks and benefits of targeting the C cascade in this group of diseases.

Disclosures

J.M.T. receives royalties from Alexion Pharmaceuticals, Inc., Cheshire, CT.

Acknowledgment

J.M.T. is supported by the National Institutes of Health grant R01 DK076690. C.M.N. is supported by the Stead Family Department of Pediatrics, University of Iowa.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

References

  1. ↵
    1. Ricklin D,
    2. Hajishengallis G,
    3. Yang K,
    4. Lambris JD
    : Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785–797, 2010
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mathern DR,
    2. Heeger PS
    : Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol 10: 1636–1650, 2015
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Walport MJ
    : Complement. First of two parts. N Engl J Med 344: 1058–1066, 2001
    OpenUrlCrossRefPubMed
  4. ↵
    1. Truedsson L,
    2. Bengtsson AA,
    3. Sturfelt G
    : Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40: 560–566, 2007
    OpenUrlCrossRefPubMed
  5. ↵
    1. Manderson AP,
    2. Botto M,
    3. Walport MJ
    : The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431–456, 2004
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hiemstra PS,
    2. Gorter A,
    3. Stuurman ME,
    4. Van Es LA,
    5. Daha MR
    : Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 17: 321–326, 1987
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ollert MW,
    2. Kadlec JV,
    3. David K,
    4. Petrella EC,
    5. Bredehorst R,
    6. Vogel CW
    : Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 153: 2213–2221, 1994
    OpenUrlAbstract
  8. ↵
    1. Wan JX,
    2. Fukuda N,
    3. Endo M,
    4. Tahira Y,
    5. Yao EH,
    6. Matsuda H,
    7. Ueno T,
    8. Matsumoto K
    : Complement 3 is involved in changing the phenotype of human glomerular mesangial cells. J Cell Physiol 213: 495–501, 2007
    OpenUrlCrossRefPubMed
  9. ↵
    1. Thurman JM,
    2. Lenderink AM,
    3. Royer PA,
    4. Coleman KE,
    5. Zhou J,
    6. Lambris JD,
    7. Nemenoff RA,
    8. Quigg RJ,
    9. Holers VM
    : C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 178: 1819–1828, 2007
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Benzaquen LR,
    2. Nicholson-Weller A,
    3. Halperin JA
    : Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179: 985–992, 1994
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Lovett DH,
    2. Haensch GM,
    3. Goppelt M,
    4. Resch K,
    5. Gemsa D
    : Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol 138: 2473–2480, 1987
    OpenUrlAbstract
  12. ↵
    1. Adler S,
    2. Baker PJ,
    3. Johnson RJ,
    4. Ochi RF,
    5. Pritzl P,
    6. Couser WG
    : Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 77: 762–767, 1986
    OpenUrlCrossRefPubMed
  13. ↵
    1. Cybulsky AV,
    2. Rennke HG,
    3. Feintzeig ID,
    4. Salant DJ
    : Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest 77: 1096–1107, 1986
    OpenUrlCrossRefPubMed
  14. ↵
    1. Zipfel PF,
    2. Skerka C
    : Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729–740, 2009
    OpenUrlCrossRefPubMed
  15. ↵
    1. Janatova J,
    2. Tack BF
    : Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component. Biochemistry 20: 2394–2402, 1981
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ichida S,
    2. Yuzawa Y,
    3. Okada H,
    4. Yoshioka K,
    5. Matsuo S
    : Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46: 89–96, 1994
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kajander T,
    2. Lehtinen MJ,
    3. Hyvärinen S,
    4. Bhattacharjee A,
    5. Leung E,
    6. Isenman DE,
    7. Meri S,
    8. Goldman A,
    9. Jokiranta TS
    : Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A 108: 2897–2902, 2011
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Józsi M,
    2. Tortajada A,
    3. Uzonyi B,
    4. Goicoechea de Jorge E,
    5. Rodríguez de Córdoba S
    : Factor H-related proteins determine complement-activating surfaces. Trends Immunol 36: 374–384, 2015
    OpenUrlCrossRefPubMed
  19. ↵
    1. Thurman JM,
    2. Ljubanović D,
    3. Royer PA,
    4. Kraus DM,
    5. Molina H,
    6. Barry NP,
    7. Proctor G,
    8. Levi M,
    9. Holers VM
    : Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116: 357–368, 2006
    OpenUrlCrossRefPubMed
  20. ↵
    1. Farrar CA,
    2. Zhou W,
    3. Lin T,
    4. Sacks SH
    : Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 20: 217–226, 2006
    OpenUrlCrossRefPubMed
  21. ↵
    1. Krisinger MJ,
    2. Goebeler V,
    3. Lu Z,
    4. Meixner SC,
    5. Myles T,
    6. Pryzdial EL,
    7. Conway EM
    : Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120: 1717–1725, 2012
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Renner B,
    2. Tong HH,
    3. Laskowski J,
    4. Jonscher K,
    5. Goetz L,
    6. Woolaver R,
    7. Hannan J,
    8. Li YX,
    9. Hourcade D,
    10. Pickering MC,
    11. Holers VM,
    12. Thurman JM
    : Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol 196: 1355–1365, 2016
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Cochrane CG,
    2. Unanue ER,
    3. Dixon FJ
    : A Role of Polymorphonuclear Leukocytes and Complement in Nephrotoxic Nephritis. J Exp Med 122: 99–116, 1965
    OpenUrlAbstract
  24. ↵
    1. Wilson CB,
    2. Dixon FJ
    : Immunopathology and glomerulonephritis. Annu Rev Med 25: 83–98, 1974
    OpenUrlCrossRefPubMed
  25. ↵
    1. Sethi S,
    2. Nasr SH,
    3. De Vriese AS,
    4. Fervenza FC
    : C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol 26: 2852–2859, 2015
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Verroust PJ,
    2. Wilson CB,
    3. Cooper NR,
    4. Edgington TS,
    5. Dixon FJ
    : Glomerular complement components in human glomerulonephritis. J Clin Invest 53: 77–84, 1974
    OpenUrlCrossRefPubMed
  27. ↵
    1. Pickering MC,
    2. D’Agati VD,
    3. Nester CM,
    4. Smith RJ,
    5. Haas M,
    6. Appel GB,
    7. Alpers CE,
    8. Bajema IM,
    9. Bedrosian C,
    10. Braun M,
    11. Doyle M,
    12. Fakhouri F,
    13. Fervenza FC,
    14. Fogo AB,
    15. Frémeaux-Bacchi V,
    16. Gale DP,
    17. Goicoechea de Jorge E,
    18. Griffin G,
    19. Harris CL,
    20. Holers VM,
    21. Johnson S,
    22. Lavin PJ,
    23. Medjeral-Thomas N,
    24. Paul Morgan B,
    25. Nast CC,
    26. Noel LH,
    27. Peters DK,
    28. Rodríguez de Córdoba S,
    29. Servais A,
    30. Sethi S,
    31. Song WC,
    32. Tamburini P,
    33. Thurman JM,
    34. Zavros M,
    35. Cook HT
    : C3 glomerulopathy: consensus report. Kidney Int 84: 1079–1089, 2013
    OpenUrlCrossRefPubMed
  28. ↵
    1. Hebert LA,
    2. Cosio FG,
    3. Neff JC
    : Diagnostic significance of hypocomplementemia. Kidney Int 39: 811–821, 1991
    OpenUrlCrossRefPubMed
  29. ↵
    1. Vallota EH,
    2. Forristal J,
    3. Spitzer RE,
    4. Davis NC,
    5. West CD
    : Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis. J Clin Invest 50: 552–558, 1971
    OpenUrlCrossRefPubMed
  30. ↵
    1. Hopkins P,
    2. Belmont HM,
    3. Buyon J,
    4. Philips M,
    5. Weissmann G,
    6. Abramson SB
    : Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31: 632–641, 1988
    OpenUrlCrossRefPubMed
  31. ↵
    1. Brenchley PE,
    2. Coupes B,
    3. Short CD,
    4. O’Donoghue DJ,
    5. Ballardie FW,
    6. Mallick NP
    : Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int 41: 933–937, 1992
    OpenUrlCrossRefPubMed
  32. ↵
    1. Bu F,
    2. Meyer NC,
    3. Zhang Y,
    4. Borsa NG,
    5. Thomas C,
    6. Nester C,
    7. Smith RJ
    : Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 65: 968–969, 2015
    OpenUrlCrossRefPubMed
  33. ↵
    1. Høgåsen K,
    2. Jansen JH,
    3. Mollnes TE,
    4. Hovdenes J,
    5. Harboe M
    : Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 95: 1054–1061, 1995
    OpenUrlCrossRefPubMed
  34. ↵
    1. Watanabe H,
    2. Garnier G,
    3. Circolo A,
    4. Wetsel RA,
    5. Ruiz P,
    6. Holers VM,
    7. Boackle SA,
    8. Colten HR,
    9. Gilkeson GS
    : Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164: 786–794, 2000
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Pickering MC,
    2. Cook HT,
    3. Warren J,
    4. Bygrave AE,
    5. Moss J,
    6. Walport MJ,
    7. Botto M
    : Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31: 424–428, 2002
    OpenUrlCrossRefPubMed
  36. ↵
    1. Xiao H,
    2. Schreiber A,
    3. Heeringa P,
    4. Falk RJ,
    5. Jennette JC
    : Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170: 52–64, 2007
    OpenUrlCrossRefPubMed
  37. ↵
    1. Lenderink AM,
    2. Liegel K,
    3. Ljubanović D,
    4. Coleman KE,
    5. Gilkeson GS,
    6. Holers VM,
    7. Thurman JM
    : The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol 293: F555–F564, 2007
    OpenUrlCrossRefPubMed
  38. ↵
    1. Weisman HF,
    2. Bartow T,
    3. Leppo MK,
    4. Marsh HC Jr.,
    5. Carson GR,
    6. Concino MF,
    7. Boyle MP,
    8. Roux KH,
    9. Weisfeldt ML,
    10. Fearon DT
    : Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146–151, 1990
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Vakeva AP,
    2. Agah A,
    3. Rollins SA,
    4. Matis LA,
    5. Li L,
    6. Stahl GL
    : Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97: 2259–2267, 1998
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Rother RP,
    2. Rollins SA,
    3. Mojcik CF,
    4. Brodsky RA,
    5. Bell L
    : Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256–1264, 2007
    OpenUrlCrossRefPubMed
  41. ↵
    1. Sahu A,
    2. Morikis D,
    3. Lambris JD
    : Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol 39: 557–566, 2003
    OpenUrlCrossRefPubMed
  42. ↵
    1. Ebanks RO,
    2. Isenman DE
    : Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol 33: 297–309, 1996
    OpenUrlCrossRefPubMed
  43. ↵
    1. Alexander JJ,
    2. Hack BK,
    3. Cunningham PN,
    4. Quigg RJ
    : A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem 276: 32129–32135, 2001
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Zhang Y,
    2. Meyer NC,
    3. Wang K,
    4. Nishimura C,
    5. Frees K,
    6. Jones M,
    7. Katz LM,
    8. Sethi S,
    9. Smith RJ
    : Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7: 265–274, 2012
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Servais A,
    2. Noël LH,
    3. Roumenina LT,
    4. Le Quintrec M,
    5. Ngo S,
    6. Dragon-Durey MA,
    7. Macher MA,
    8. Zuber J,
    9. Karras A,
    10. Provot F,
    11. Moulin B,
    12. Grünfeld JP,
    13. Niaudet P,
    14. Lesavre P,
    15. Frémeaux-Bacchi V
    : Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82: 454–464, 2012
    OpenUrlCrossRefPubMed
  46. ↵
    1. Noris M,
    2. Remuzzi G
    : Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676–1687, 2009
    OpenUrlCrossRefPubMed
  47. ↵
    1. Bresin E,
    2. Rurali E,
    3. Caprioli J,
    4. Sanchez-Corral P,
    5. Fremeaux-Bacchi V,
    6. Rodriguez de Cordoba S,
    7. Pinto S,
    8. Goodship TH,
    9. Alberti M,
    10. Ribes D,
    11. Valoti E,
    12. Remuzzi G,
    13. Noris M
    ; European Working Party on Complement Genetics in Renal Diseases: Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24: 475–486, 2013
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Venables JP,
    2. Strain L,
    3. Routledge D,
    4. Bourn D,
    5. Powell HM,
    6. Warwicker P,
    7. Diaz-Torres ML,
    8. Sampson A,
    9. Mead P,
    10. Webb M,
    11. Pirson Y,
    12. Jackson MS,
    13. Hughes A,
    14. Wood KM,
    15. Goodship JA,
    16. Goodship TH
    : Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3: e431, 2006
    OpenUrlCrossRefPubMed
    1. Maga TK,
    2. Meyer NC,
    3. Belsha C,
    4. Nishimura CJ,
    5. Zhang Y,
    6. Smith RJ
    : A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. Nephrol Dial Transplant 26: 739–741, 2011
    OpenUrlCrossRefPubMed
    1. Eyler SJ,
    2. Meyer NC,
    3. Zhang Y,
    4. Xiao X,
    5. Nester CM,
    6. Smith RJ
    : A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome. Pediatr Nephrol 28: 2221–2225, 2013
    OpenUrlCrossRefPubMed
    1. Valoti E,
    2. Alberti M,
    3. Tortajada A,
    4. Garcia-Fernandez J,
    5. Gastoldi S,
    6. Besso L,
    7. Bresin E,
    8. Remuzzi G,
    9. Rodriguez de Cordoba S,
    10. Noris M
    : A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol 26: 209–219, 2015
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Francis NJ,
    2. McNicholas B,
    3. Awan A,
    4. Waldron M,
    5. Reddan D,
    6. Sadlier D,
    7. Kavanagh D,
    8. Strain L,
    9. Marchbank KJ,
    10. Harris CL,
    11. Goodship TH
    : A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 119: 591–601, 2012
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Dragon-Durey MA,
    2. Sethi SK,
    3. Bagga A,
    4. Blanc C,
    5. Blouin J,
    6. Ranchin B,
    7. André JL,
    8. Takagi N,
    9. Cheong HI,
    10. Hari P,
    11. Le Quintrec M,
    12. Niaudet P,
    13. Loirat C,
    14. Fridman WH,
    15. Frémeaux-Bacchi V
    : Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21: 2180–2187, 2010
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Sethi S,
    2. Fervenza FC,
    3. Zhang Y,
    4. Zand L,
    5. Vrana JA,
    6. Nasr SH,
    7. Theis JD,
    8. Dogan A,
    9. Smith RJ
    : C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82: 465–473, 2012
    OpenUrlCrossRefPubMed
  55. ↵
    1. Servais A,
    2. Frémeaux-Bacchi V,
    3. Lequintrec M,
    4. Salomon R,
    5. Blouin J,
    6. Knebelmann B,
    7. Grünfeld JP,
    8. Lesavre P,
    9. Noël LH,
    10. Fakhouri F
    : Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44: 193–199, 2007
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Tortajada A,
    2. Yébenes H,
    3. Abarrategui-Garrido C,
    4. Anter J,
    5. García-Fernández JM,
    6. Martínez-Barricarte R,
    7. Alba-Domínguez M,
    8. Malik TH,
    9. Bedoya R,
    10. Cabrera Pérez R,
    11. López Trascasa M,
    12. Pickering MC,
    13. Harris CL,
    14. Sánchez-Corral P,
    15. Llorca O,
    16. Rodríguez de Córdoba S
    : C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123: 2434–2446, 2013
    OpenUrlCrossRefPubMed
  57. ↵
    1. Martínez-Barricarte R,
    2. Heurich M,
    3. Valdes-Cañedo F,
    4. Vazquez-Martul E,
    5. Torreira E,
    6. Montes T,
    7. Tortajada A,
    8. Pinto S,
    9. Lopez-Trascasa M,
    10. Morgan BP,
    11. Llorca O,
    12. Harris CL,
    13. Rodríguez de Córdoba S
    : Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120: 3702–3712, 2010
    OpenUrlCrossRefPubMed
  58. ↵
    1. Loirat C,
    2. Fakhouri F,
    3. Ariceta G,
    4. Besbas N,
    5. Bitzan M,
    6. Bjerre A,
    7. Coppo R,
    8. Emma F,
    9. Johnson S,
    10. Karpman D,
    11. Landau D,
    12. Langman CB,
    13. Lapeyraque AL,
    14. Licht C,
    15. Nester C,
    16. Pecoraro C,
    17. Riedl M,
    18. van de Kar NC,
    19. Van de Walle J,
    20. Vivarelli M,
    21. Fremeaux-Bacchi V
    : for HUSI: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31: 15–39, 2015
    OpenUrlPubMed
  59. ↵
    1. Fries LF,
    2. Gaither TA,
    3. Hammer CH,
    4. Frank MM
    : C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 160: 1640–1655, 1984
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Quigg RJ,
    2. Lim A,
    3. Haas M,
    4. Alexander JJ,
    5. He C,
    6. Carroll MC
    : Immune complex glomerulonephritis in C4- and C3-deficient mice. Kidney Int 53: 320–330, 1998
    OpenUrlCrossRefPubMed
  61. ↵
    1. Noris M,
    2. Caprioli J,
    3. Bresin E,
    4. Mossali C,
    5. Pianetti G,
    6. Gamba S,
    7. Daina E,
    8. Fenili C,
    9. Castelletti F,
    10. Sorosina A,
    11. Piras R,
    12. Donadelli R,
    13. Maranta R,
    14. van der Meer I,
    15. Conway EM,
    16. Zipfel PF,
    17. Goodship TH,
    18. Remuzzi G
    : Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844–1859, 2010
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Chua JS,
    2. Baelde HJ,
    3. Zandbergen M,
    4. Wilhelmus S,
    5. van Es LA,
    6. de Fijter JW,
    7. Bruijn JA,
    8. Bajema IM,
    9. Cohen D
    : Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol 26: 2239–2247, 2015
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Laskowski J,
    2. Renner B,
    3. Le Quintrec M,
    4. Panzer S,
    5. Hannan JP,
    6. Ljubanovic D,
    7. Ruseva MM,
    8. Borza DB,
    9. Antonioli AH,
    10. Pickering MC,
    11. Holers VM,
    12. Thurman JM
    : Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int 2016, in press
  64. ↵
    1. Beck LH Jr.,
    2. Bonegio RG,
    3. Lambeau G,
    4. Beck DM,
    5. Powell DW,
    6. Cummins TD,
    7. Klein JB,
    8. Salant DJ
    : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009
    OpenUrlCrossRefPubMed
  65. ↵
    1. Tomas NM,
    2. Beck LH Jr.,
    3. Meyer-Schwesinger C,
    4. Seitz-Polski B,
    5. Ma H,
    6. Zahner G,
    7. Dolla G,
    8. Hoxha E,
    9. Helmchen U,
    10. Dabert-Gay AS,
    11. Debayle D,
    12. Merchant M,
    13. Klein J,
    14. Salant DJ,
    15. Stahl RA,
    16. Lambeau G
    : Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371: 2277–2287, 2014
    OpenUrlCrossRefPubMed
  66. ↵
    1. Teixeira JE,
    2. Costa RS,
    3. Lachmann PJ,
    4. Würzner R,
    5. Barbosa JE
    : CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. Clin Exp Immunol 105: 497–503, 1996
    OpenUrlCrossRefPubMed
  67. ↵
    1. Floege J,
    2. Moura IC,
    3. Daha MR
    : New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol 36: 431–442, 2014
    OpenUrlCrossRefPubMed
  68. ↵
    1. Maillard N,
    2. Wyatt RJ,
    3. Julian BA,
    4. Kiryluk K,
    5. Gharavi A,
    6. Fremeaux-Bacchi V,
    7. Novak J
    : Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol 26: 1503–1512, 2015
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Gharavi AG,
    2. Kiryluk K,
    3. Choi M,
    4. Li Y,
    5. Hou P,
    6. Xie J,
    7. Sanna-Cherchi S,
    8. Men CJ,
    9. Julian BA,
    10. Wyatt RJ,
    11. Novak J,
    12. He JC,
    13. Wang H,
    14. Lv J,
    15. Zhu L,
    16. Wang W,
    17. Wang Z,
    18. Yasuno K,
    19. Gunel M,
    20. Mane S,
    21. Umlauf S,
    22. Tikhonova I,
    23. Beerman I,
    24. Savoldi S,
    25. Magistroni R,
    26. Ghiggeri GM,
    27. Bodria M,
    28. Lugani F,
    29. Ravani P,
    30. Ponticelli C,
    31. Allegri L,
    32. Boscutti G,
    33. Frasca G,
    34. Amore A,
    35. Peruzzi L,
    36. Coppo R,
    37. Izzi C,
    38. Viola BF,
    39. Prati E,
    40. Salvadori M,
    41. Mignani R,
    42. Gesualdo L,
    43. Bertinetto F,
    44. Mesiano P,
    45. Amoroso A,
    46. Scolari F,
    47. Chen N,
    48. Zhang H,
    49. Lifton RP
    : Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321–327, 2011
    OpenUrlCrossRefPubMed
  70. ↵
    1. Zhai YL,
    2. Meng SJ,
    3. Zhu L,
    4. Shi SF,
    5. Wang SX,
    6. Liu LJ,
    7. Lv JC,
    8. Yu F,
    9. Zhao MH,
    10. Zhang H
    : Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy [published online ahead of print January 29, 2016]. J Am Soc Nephrol doi:10.1681/ASN.2015010012
  71. ↵
    1. Hsu SI,
    2. Couser WG
    : Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 14[Suppl 2]: S186–S191, 2003
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Sheerin NS,
    2. Risley P,
    3. Abe K,
    4. Tang Z,
    5. Wong W,
    6. Lin T,
    7. Sacks SH
    : Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J 22: 1065–1072, 2008
    OpenUrlCrossRefPubMed
  73. ↵
    1. Nath KA,
    2. Hostetter MK,
    3. Hostetter TH
    : Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76: 667–675, 1985
    OpenUrlCrossRefPubMed
  74. ↵
    1. Fremeaux-Bacchi V,
    2. Fakhouri F,
    3. Garnier A,
    4. Bienaimé F,
    5. Dragon-Durey MA,
    6. Ngo S,
    7. Moulin B,
    8. Servais A,
    9. Provot F,
    10. Rostaing L,
    11. Burtey S,
    12. Niaudet P,
    13. Deschênes G,
    14. Lebranchu Y,
    15. Zuber J,
    16. Loirat C
    : Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554–562, 2013
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Bhattacharjee A,
    2. Reuter S,
    3. Trojnár E,
    4. Kolodziejczyk R,
    5. Seeberger H,
    6. Hyvärinen S,
    7. Uzonyi B,
    8. Szilágyi Á,
    9. Prohászka Z,
    10. Goldman A,
    11. Józsi M,
    12. Jokiranta TS
    : The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 290: 9500–9510, 2015
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. Pickering MC,
    2. de Jorge EG,
    3. Martinez-Barricarte R,
    4. Recalde S,
    5. Garcia-Layana A,
    6. Rose KL,
    7. Moss J,
    8. Walport MJ,
    9. Cook HT,
    10. de Córdoba SR,
    11. Botto M
    : Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204: 1249–1256, 2007
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Legendre CM,
    2. Licht C,
    3. Muus P,
    4. Greenbaum LA,
    5. Babu S,
    6. Bedrosian C,
    7. Bingham C,
    8. Cohen DJ,
    9. Delmas Y,
    10. Douglas K,
    11. Eitner F,
    12. Feldkamp T,
    13. Fouque D,
    14. Furman RR,
    15. Gaber O,
    16. Herthelius M,
    17. Hourmant M,
    18. Karpman D,
    19. Lebranchu Y,
    20. Mariat C,
    21. Menne J,
    22. Moulin B,
    23. Nürnberger J,
    24. Ogawa M,
    25. Remuzzi G,
    26. Richard T,
    27. Sberro-Soussan R,
    28. Severino B,
    29. Sheerin NS,
    30. Trivelli A,
    31. Zimmerhackl LB,
    32. Goodship T,
    33. Loirat C
    : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169–2181, 2013
    OpenUrlCrossRefPubMed
  78. ↵
    1. Greenbaum LA,
    2. Fila M,
    3. Ardissino G,
    4. Al-Akash SI,
    5. Evans J,
    6. Henning P,
    7. Lieberman KV,
    8. Maringhini S,
    9. Pape L,
    10. Rees L,
    11. van de Kar NC,
    12. Vande Walle J,
    13. Ogawa M,
    14. Bedrosian CL,
    15. Licht C
    : Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89: 701–711, 2016
    OpenUrlCrossRefPubMed
  79. ↵
    1. Nishimura J,
    2. Yamamoto M,
    3. Hayashi S,
    4. Ohyashiki K,
    5. Ando K,
    6. Brodsky AL,
    7. Noji H,
    8. Kitamura K,
    9. Eto T,
    10. Takahashi T,
    11. Masuko M,
    12. Matsumoto T,
    13. Wano Y,
    14. Shichishima T,
    15. Shibayama H,
    16. Hase M,
    17. Li L,
    18. Johnson K,
    19. Lazarowski A,
    20. Tamburini P,
    21. Inazawa J,
    22. Kinoshita T,
    23. Kanakura Y
    : Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370: 632–639, 2014
    OpenUrlCrossRefPubMed
  80. ↵
    1. Zuber J,
    2. Quintrec ML,
    3. Krid S,
    4. Bertoye C,
    5. Gueutin V,
    6. Lahoche A,
    7. Heyne N,
    8. Ardissino G,
    9. Chatelet V,
    10. Noel LH,
    11. Hourmant M,
    12. Niaudet P,
    13. Frémeaux-Bacchi V
    , Rondeau E, Legendre C, Loirat C: Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. Am J Transplant 12: 3337–3354, 2012
    OpenUrlCrossRefPubMed
  81. ↵
    1. Tang Z,
    2. Lu B,
    3. Hatch E,
    4. Sacks SH,
    5. Sheerin NS
    : C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 20: 593–603, 2009
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Rose KL,
    2. Paixao-Cavalcante D,
    3. Fish J,
    4. Manderson AP,
    5. Malik TH,
    6. Bygrave AE,
    7. Lin T,
    8. Sacks SH,
    9. Walport MJ,
    10. Cook HT,
    11. Botto M,
    12. Pickering MC
    : Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 118: 608–618, 2008
    OpenUrlPubMed
  83. ↵
    1. Nester CM,
    2. Barbour T,
    3. de Cordoba SR,
    4. Dragon-Durey MA,
    5. Fremeaux-Bacchi V,
    6. Goodship TH,
    7. Kavanagh D,
    8. Noris M,
    9. Pickering M,
    10. Sanchez-Corral P,
    11. Skerka C,
    12. Zipfel P,
    13. Smith RJ
    : Atypical aHUS: State of the art. Mol Immunol 67: 31–42, 2015
    OpenUrlCrossRefPubMed
  84. ↵
    1. Fakhouri F,
    2. Roumenina L,
    3. Provot F,
    4. Sallée M,
    5. Caillard S,
    6. Couzi L,
    7. Essig M,
    8. Ribes D,
    9. Dragon-Durey MA,
    10. Bridoux F,
    11. Rondeau E,
    12. Frémeaux-Bacchi V
    : Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21: 859–867, 2010
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Vivarelli M,
    2. Emma F
    : Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40: 472–477, 2014
    OpenUrlCrossRefPubMed
  86. ↵
    1. Shapira I,
    2. Andrade D,
    3. Allen SL,
    4. Salmon JE
    : Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64: 2719–2723, 2012
    OpenUrlCrossRefPubMed
  87. ↵
    1. Pickering MC,
    2. Ismajli M,
    3. Condon MB,
    4. McKenna N,
    5. Hall AE,
    6. Lightstone L,
    7. Terence Cook H,
    8. Cairns TD
    : Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54: 2286–2288, 2015
    OpenUrlCrossRefPubMed
  88. ↵
    1. Rosenblad T,
    2. Rebetz J,
    3. Johansson M,
    4. Békássy Z,
    5. Sartz L,
    6. Karpman D
    : Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29: 2225–2228, 2014
    OpenUrlCrossRefPubMed
  89. ↵
    1. Ricklin D,
    2. Lambris JD
    : Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 190: 3839–3847, 2013
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Xiao H,
    2. Dairaghi DJ,
    3. Powers JP,
    4. Ertl LS,
    5. Baumgart T,
    6. Wang Y,
    7. Seitz LC,
    8. Penfold ME,
    9. Gan L,
    10. Hu P,
    11. Lu B,
    12. Gerard NP,
    13. Gerard C,
    14. Schall TJ,
    15. Jaen JC,
    16. Falk RJ,
    17. Jennette JC
    : C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25: 225–231, 2014
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Thurman JM,
    2. Le Quintrec M
    : Targeting the Complement Cascade: Novel Treatments Coming down the Pike. Kidney Int 2016, in press
  92. ↵
    1. Skattum L,
    2. van Deuren M,
    3. van der Poll T,
    4. Truedsson L
    : Complement deficiency states and associated infections. Mol Immunol 48: 1643–1655, 2011
    OpenUrlCrossRefPubMed
  93. ↵
    1. Kelly RJ,
    2. Hill A,
    3. Arnold LM,
    4. Brooksbank GL,
    5. Richards SJ,
    6. Cullen M,
    7. Mitchell LD,
    8. Cohen DR,
    9. Gregory WM,
    10. Hillmen P
    : Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117: 6786–6792, 2011
    OpenUrlAbstract/FREE Full Text
    1. Noris M,
    2. Galbusera M,
    3. Gastoldi S,
    4. Macor P,
    5. Banterla F,
    6. Bresin E,
    7. Tripodo C,
    8. Bettoni S,
    9. Donadelli R,
    10. Valoti E,
    11. Tedesco F,
    12. Amore A,
    13. Coppo R,
    14. Ruggenenti P,
    15. Gotti E,
    16. Remuzzi G
    : Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124: 1715–1726, 2014
    OpenUrlAbstract/FREE Full Text
    1. Haas M,
    2. Eustace JA
    : Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int 65: 2145–2152, 2004
    OpenUrlCrossRefPubMed
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
All Things Complement
Joshua M. Thurman, Carla M. Nester
CJASN Oct 2016, 11 (10) 1856-1866; DOI: 10.2215/CJN.01710216
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords